Acute Lung Injury: How Inflammation, Oxidative Stress and Nanomedicine Shape Outcomes

Acute lung injury (ALI) affects approximately 78.9 per 100,000 adults in the United States annually, with mortality rates between 38–46% depending on severity. The condition can be triggered by direct pulmonary insults (trauma, pneumonia, toxic inhalation) or indirect systemic events (sepsis, pancreatitis, drug toxicity), both converging on alveolar epithelial and capillary endothelial cell damage. If untreated, ALI progresses to ARDS, multiple organ failure, and death. COVID-19 has further elevated global incidence and mortality, intensifying the urgency of mechanistic understanding and treatment innovation.

The review identifies six major, interconnected pathogenic mechanisms. First, inflammatory cytokines—particularly TNF-α, IL-6, IL-8, and IL-1β—are released following pattern recognition receptor activation on macrophages and epithelial cells. Direct lung injury produces four times more inflammatory cells in bronchoalveolar lavage fluid than indirect injury, with inflammation persisting up to three weeks. Second, the NLRP3 inflammasome serves as a molecular bridge amplifying early inflammation: upon activation by PAMPs, DAMPs, ATP, or ROS, it assembles and cleaves pro-caspase-1, triggering IL-1β and IL-18 maturation. NLRP3 activation has been demonstrated in hemorrhagic shock, mechanical stretch, and LPS-combined ventilator models. Third, oxidative stress arises when ROS generation overwhelms antioxidant defenses (glutathione, catalase, superoxide dismutase), peroxidizing membrane lipids, increasing permeability, and upregulating inflammatory adhesion molecules—driving pulmonary edema and impaired gas exchange.

Fourth, apoptosis of alveolar epithelial and endothelial cells is mediated via both intrinsic (mitochondrial) and extrinsic (death receptor) pathways, directly eroding the structural integrity of the alveolar-capillary membrane. Fifth, mitochondrial dysfunction—manifesting as impaired ATP synthesis, increased membrane permeability, and release of pro-apoptotic factors like cytochrome c—amplifies both oxidative stress and inflammatory signaling in a self-reinforcing cycle. Sixth, disruption of the pulmonary epithelial and endothelial barriers results in non-cardiogenic pulmonary edema, the hallmark of ALI, driven by tight junction protein degradation and cytoskeletal remodeling downstream of the above mechanisms.

On the treatment side, the review evaluates lung-protective mechanical ventilation (low tidal volume strategies), conservative fluid management to limit edema, and mesenchymal stem cell (MSC) therapy, which shows immunomodulatory and barrier-repair potential in preclinical models. Pharmacologic approaches targeting NF-κB, NLRP3, and ROS pathways are reviewed. Crucially, the authors highlight advanced nanomedicine platforms—including lipid nanoparticles, polymeric nanoparticles, and exosome-based carriers—as emerging tools for precise pulmonary drug delivery, potentially overcoming bioavailability and off-target limitations of conventional agents.

Caveats include the review's reliance on animal models for much mechanistic evidence, with limited large-scale clinical trial data for newer therapies. Nanomedicine applications remain largely preclinical. The multifactorial nature of ALI means no single therapeutic target has yet translated to a definitive clinical intervention.